Asymmetric dimethylarginine compartmental behavior during high-flux hemodialysis

References

• Collins AJ, Foley RN, Chavers B, et al. USRDS 2011 ADR: ESRD providers. Am J Kidney Dis. 2012;59:A7.
   PubMedGoogle Scholar
• Tripepi G, Raso FM, Sijbrands E, et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol. 2011;6(7):1714–1721.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358(9299):2113–2117.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl. 2003; 63:S105–S110.
   Web of Science ®Google Scholar
• Teerlink T. ADMA metabolism and clearance. Vasc Med. 2005;10:S73–S81.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Benedetto FA, Maas R, CREED Investigators, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol. 2002;13(2):490–496.
   PubMed Web of Science ®Google Scholar
• Shafi T, Hostetter TH, Meyer TW, et al. Serum asymmetric and symmetric dimethylarginine and morbidity and mortality in hemodialysis patients. Am J Kidney Dis. 2017;70(1):48–58.
   PubMed Web of Science ®Google Scholar
• Zhou S, Zhu Q, Li X, et al. Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis. Sci Rep. 2017;7:44692.
   PubMed Web of Science ®Google Scholar
• Kalousova M, Kielstein JT, Hodkova M, et al. No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients. Blood Purif. 2006;24(5–6):439–444.
   PubMed Web of Science ®Google Scholar
• Grooteman MP, Wauters IM, Teerlink T, et al. Plasma dimethylarginine levels in chronic hemodialysis patients are independent of the type of dialyzer applied. Blood Purif. 2007;25(3):281–289.
   PubMed Web of Science ®Google Scholar
• Mochizuki S, Ono J, Yada T, et al. Systemic nitric oxide production rate during hemodialysis and its relationship with nitric oxide-related factors. Blood Purif. 2005;23(4):317–324.
   PubMed Web of Science ®Google Scholar
• Vanholder R, Pletinck A, Schepers E, et al. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins (Basel). 2018;10(1):33.
   PubMed Web of Science ®Google Scholar
• Eloot S, Torremans A, Smet R, et al. Kinetic behavior of urea is different from that of other water-soluble compounds the case of the guanidino compounds. Kidney Int. 2005;67(4):1566–1575.
   PubMed Web of Science ®Google Scholar
• Eloot S, Torremans A, De Smet R, et al. Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis. 2007;50(2):279–288.
   PubMed Web of Science ®Google Scholar
• Billecke SS, Kitzmiller LA, Northrup JJ, et al. Contribution of whole blood to the control of plasma asymmetrical dimethylarginine. Am J Physiol Heart Circ Physiol. 2006;291(4):H1788–96.
   PubMed Web of Science ®Google Scholar
• Billecke SS, D'Alecy LG, Platel R, et al. Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease. Nephrol Dial Transplant. 2008;24(2):489–496.
   PubMed Web of Science ®Google Scholar
• Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. 1993;4(5):1205–1213.
   PubMed Web of Science ®Google Scholar
• Polinder-Bos HA, Garcia DV, Kuipers J, et al. Hemodialysis induces an acute decline in cerebral blood flow in elderly patients. J Am Soc Nephrol. 2018;29(4):1317–1325.
   PubMed Web of Science ®Google Scholar
• Ponda MP, Quan Z, Melamed ML, et al. Methylamine clearance by haemodialysis is low. Nephrol Dial Transplant. 2010;25(5):1608–1613.
   PubMed Web of Science ®Google Scholar
• Montagnana M, Lippi G, Tessitore N, et al. Effect of hemodialysis on traditional and innovative cardiac markers. J Clin Lab Anal. 2008;22(1):59–65.
   PubMed Web of Science ®Google Scholar
• Schwedhelm E, Maas R, Tan-Andresen J, et al. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851(1–2):211–219.
   PubMed Web of Science ®Google Scholar
• Kalantari S, Nafar M. An update of urine and blood metabolomics in chronic kidney disease. Biomark Med. 2019;13(7):577–597.
   PubMed Web of Science ®Google Scholar
• Meyer TW, Leeper EC, Bartlett DW, et al. Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes. J Am Soc Nephrol. 2004;15(7):1927–1935.
   PubMed Web of Science ®Google Scholar
• Curran RE, Claxton CR, Hutchison L, et al. Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding. Drug Metab Dispos. 2011;39(3):551–557.
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Boger RH, Bode-Boger SM, et al. Low dialysance of asymmetric dimethylarginine (ADMA)-in vivo and in vitro evidence of significant protein binding. CN. 2004;62(10):295–300.
   Google Scholar
• Tsikas D, Engeli S, Beckmann B, et al. Asymmetric dimethylarginine (ADMA) is present in plasma proteins of healthy subjects at the low nmol-per-g-level. Nitric Oxide. 2010;22(4):316–317.
   PubMed Web of Science ®Google Scholar
• Tsikas D, Beckmann B. Albumin from human serum does not contain asymmetric dimethylarginine (ADMA). Clin Biochem. 2009;42(16–17):1739–1740.
   PubMed Web of Science ®Google Scholar
• Rifai K, Bode-Boeger SM, Martens-Lobenhoffer J. Removal of asymmetric dimethylarginine during artificial liver support using fractionated plasma separation and adsorption. Scand J Gastroenterol. 2010;45(9):1110–1115.
   PubMed Web of Science ®Google Scholar
• MacAllister RJ, Rambausek MH, Vallance P, et al. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant. 1996;11(12):2449–2452.
   PubMed Web of Science ®Google Scholar
• Achinger SG, Ayus JC. The role of daily dialysis in the control of hyperphosphatemia. Kidney Int Suppl. 2005;67:S28–S32.
   Google Scholar
• Leypoldt JK. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration. Semin Dial. 2005;18(5):401–408.
   PubMed Web of Science ®Google Scholar
• Mucsi I, Hercz G, Uldall R, et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998;53(5):1399–1404.
   PubMed Web of Science ®Google Scholar
• Zhang DL, Liu J, Liu S, et al. The differences of asymmetric dimethylarginine removal by different dialysis treatments. Ren Fail. 2010;32(8):935–940.
   PubMed Web of Science ®Google Scholar